Cercar
01/01/2023
Risk-of-bias assessment of the randomized clinical trials and systematic reviews on surgical treatments for breast cancer-related lymphedema: A mapping review
Al-Sakkaf A.M., Bonfill X., Ardiles-Ruesjas S., Bendersky-Kohan J., Sola I., Masia J.. Risk-of-bias assessment of the randomized clinical trials and systematic reviews on surgical treatments for breast cancer-related lymphedema: A mapping review. Journal of Plastic Reconstructive and Aesthetic Surgery. 2023; 84DOI:10.1016/j.bjps.2023.05.002. PMID:37329747. IF:2.000(Q2/4D).
01/01/2023
Occupational health. Concepts and techniques for the prevention of occupational hazards
Cortes-Franch, I. Occupational health. Concepts and techniques for the prevention of occupational hazards. Gaceta Sanitaria. 2023; 37DOI:10.1016/j.gaceta.2022.102263. PMID:. IF:1.500(Q3/7D).
01/01/2023
Effect of COVID-19 prevention as part of an urban renewal programme
Fernández-Barrés S., Perez G., Piñero M., Reyes A., Pérez K., Artazcoz L., Borrell C.. Effect of COVID-19 prevention as part of an urban renewal programme. PUBLIC HEALTH. 2023; 223DOI:10.1016/j.puhe.2023.07.014. PMID:37666182. IF:3.900(Q1/2D).
01/01/2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.. JCO Precision Oncology. 2023; 7DOI:10.1200/PO.22.00258. PMID:36716415. IF:5.300(Q1/2D).